- ¥293bn
- ¥279bn
- ¥354bn
Table: Fujitsu General -2021/22 group forecast
Table: Fujitsu General - 9-MTH group results
Table: Fujitsu General - 6-MTH group results
Table: Fujitsu General -Q1 group results
Table: Fujitsu General -2020/21 group results
Table: Fujitsu General -2020/21 parent results
RCS - Immune Pharmaceuticl - Immune Pharmaceuticals Proposal to Exit Bankruptcy
Table: Fujitsu General - 9-MTH group results
Table: Fujitsu General - 6-MTH group results
2020 6-month group forecast
Table: Fujitsu General -2020/21 group forecast
Table: Fujitsu General -Q1 group results
Table: Fujitsu General -2020/21 div forecast
2020 6-month group forecast
Table: Fujitsu General -2020/21 group forecast
Table: Fujitsu General -2019/20 group results
Table: Fujitsu General -2019/20 parent results
Table: Fujitsu General - 9-MTH group results
Table: Fujitsu General - 6-MTH group results